Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00638118 · ClinicalTrials.gov registry record · Phase 4
Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen
A Phase 4 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 48
- Enrollment target
NCT00638118 is a Phase 4 study that has completed, run by Sanofi. The registered enrollment target is 48 participants.
The verdict
NCT00638118, a Phase 4 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 48 participants
- Enrollment target
Study Summary
Examine the relative potency, onset of action and duration of action of fexofenadine HCl 180 mg (Allegra) and montelukast sodium 10 mg (Singulair) as compared to placebo on skin wheals and flares induced by seasonal allergen.
Interventions
- DRUG Fexofenadine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2003-02 |
| Est. Completion | 2003-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00638118
The ClinicalTrials.gov registry entry for NCT00638118 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fexofenadine is the first listed.
NCT00638118 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00638118 about?
NCT00638118 is a clinical study titled "Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen". Examine the relative potency, onset of action and duration of action of fexofenadine HCl 180 mg (Allegra) and montelukast sodium 10 mg (Singulair) as compared to placebo on skin wheals and flares induced by seasonal allergen.
What is the current status of trial NCT00638118?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 2003-02. Estimated completion is 2003-05.
What interventions are being tested in trial NCT00638118?
The interventions under investigation include: Fexofenadine (DRUG).
Who is sponsoring clinical trial NCT00638118?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.